Omnicell (NASDAQ:OMCL) Sets New 12-Month High – Should You Buy?

Shares of Omnicell, Inc. (NASDAQ:OMCL) hit a new 52-week high during trading on Wednesday . The company traded as high as $52.51 and last traded at $52.04, with a volume of 183675 shares trading hands. The stock had previously closed at $40.12.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on OMCL. Bank of America reiterated a “neutral” rating and issued a $57.00 price objective (up from $44.00) on shares of Omnicell in a research note on Thursday. Barclays lifted their price target on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday. Wells Fargo & Company increased their price objective on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Craig Hallum lifted their target price on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday. Finally, StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 19th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $49.14.

Omnicell Price Performance

The company has a 50 day moving average of $43.26 and a 200-day moving average of $35.17. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 1.05.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a positive return on equity of 2.55% and a negative net margin of 1.66%. The firm had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. During the same quarter last year, the company posted $0.29 EPS. The company’s revenue for the quarter was down 7.4% on a year-over-year basis. Equities research analysts anticipate that Omnicell, Inc. will post 0.64 EPS for the current year.

Institutional Investors Weigh In On Omnicell

Hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after buying an additional 553 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after acquiring an additional 1,000 shares in the last quarter. 1620 Investment Advisors Inc. increased its stake in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after acquiring an additional 1,542 shares during the last quarter. EntryPoint Capital LLC increased its stake in Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares during the last quarter. Finally, CWM LLC raised its position in Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.